Aclaris Therapeutics, Inc. (ACRS)
ACRS Stock Price Chart
Explore Aclaris Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze ACRS price movements and trends.
ACRS Company Profile
Discover essential business fundamentals and corporate details for Aclaris Therapeutics, Inc. (ACRS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
6 Oct 2015
Employees
61.00
Website
https://www.aclaristx.comCEO
Neal S. Walker D.O.,
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
ACRS Financial Timeline
Browse a chronological timeline of Aclaris Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.13, while revenue estimate is $1.59M.
Earnings released on 7 Aug 2025
EPS came in at -$0.13 matching the estimated -$0.13, while revenue for the quarter reached $1.78M , beating expectations by +56.22%.
Earnings released on 8 May 2025
EPS came in at -$0.12 surpassing the estimated -$0.17 by +29.41%, while revenue for the quarter reached $1.46M , missing expectations by -59.01%.
Earnings released on 27 Feb 2025
EPS came in at -$0.10 falling short of the estimated -$0.09 by -11.11%, while revenue for the quarter reached $9.21M , beating expectations by +30.82%.
Earnings released on 6 Nov 2024
EPS came in at -$0.11 falling short of the estimated -$0.08 by -37.50%, while revenue for the quarter reached $4.35M , beating expectations by +105.00%.
Earnings released on 7 Aug 2024
EPS came in at -$0.15 surpassing the estimated -$0.19 by +21.05%, while revenue for the quarter reached $2.77M , beating expectations by +51.98%.
Earnings released on 7 May 2024
EPS came in at -$0.24 surpassing the estimated -$0.28 by +14.29%, while revenue for the quarter reached $2.40M , beating expectations by +75.04%.
Earnings released on 27 Feb 2024
EPS came in at -$0.30 surpassing the estimated -$0.37 by +18.92%, while revenue for the quarter reached $17.57M , beating expectations by +422.92%.
Earnings released on 6 Nov 2023
EPS came in at -$0.41 surpassing the estimated -$0.48 by +14.58%, while revenue for the quarter reached $9.28M , beating expectations by +491.21%.
Earnings released on 7 Aug 2023
EPS came in at -$0.42 surpassing the estimated -$0.45 by +6.67%, while revenue for the quarter reached $1.87M , missing expectations by -1.63%.
Earnings released on 8 May 2023
EPS came in at -$0.42 surpassing the estimated -$0.44 by +4.55%, while revenue for the quarter reached $2.53M , beating expectations by +44.46%.
Earnings released on 23 Feb 2023
EPS came in at -$0.41 surpassing the estimated -$0.46 by +10.87%, while revenue for the quarter reached $7.75M , beating expectations by +288.82%.
Earnings released on 8 Nov 2022
EPS came in at -$0.30 surpassing the estimated -$0.39 by +23.08%, while revenue for the quarter reached $19.02M , beating expectations by +1.09K%.
Earnings released on 3 Aug 2022
EPS came in at -$0.31 surpassing the estimated -$0.36 by +13.89%, while revenue for the quarter reached $1.53M , missing expectations by -5.20%.
Earnings released on 10 May 2022
EPS came in at -$0.31 surpassing the estimated -$0.39 by +20.51%, while revenue for the quarter reached $1.45M , missing expectations by -9.10%.
Earnings released on 24 Feb 2022
EPS came in at -$0.37 falling short of the estimated -$0.36 by -2.78%, while revenue for the quarter reached $1.50M , missing expectations by -16.20%.
Earnings released on 2 Nov 2021
EPS came in at -$0.35 falling short of the estimated -$0.27 by -29.63%, while revenue for the quarter reached $1.66M , missing expectations by -6.27%.
Earnings released on 5 Aug 2021
EPS came in at -$0.34 falling short of the estimated -$0.26 by -30.77%, while revenue for the quarter reached $1.82M , beating expectations by +4.23%.
Earnings released on 7 May 2021
EPS came in at -$0.57 falling short of the estimated -$0.27 by -111.11%, while revenue for the quarter reached $1.78M , beating expectations by +2.87%.
Earnings released on 25 Feb 2021
EPS came in at -$0.31 falling short of the estimated -$0.28 by -10.71%, while revenue for the quarter reached $1.58M , beating expectations by +12.50%.
Earnings released on 4 Nov 2020
EPS came in at -$0.25 surpassing the estimated -$0.29 by +13.79%, while revenue for the quarter reached $1.45M , missing expectations by -14.29%.
ACRS Stock Performance
Access detailed ACRS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.